The German biopharmaceutical company CureVac states that according to the results of the second phase of the interim trials, CVnCoV vaccine has not reached the expected results of efficiency as the company reported.
“In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria,” the message says.
The result of the interim analysis showed 134 cases of Covid-19 infection. About 40,000 volunteers from Europe and Latin America participated in the research. The company noted that one case of infection was tied with the final version of SARS-CoV-2 coronavirus that appeared in Wuhan. 57% of cases were related to the so-called variants that cause concerns.
Besides, it is specified that interim results of the analysis show that the vaccine is efficient for younger partakers. It did not prove the efficiency for people over the age of 60 who amenable to more serious forms of the disease.
“While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging. As we are continuing toward the final analysis with a minimum of 80 additional cases, the overall vaccine efficacy may change,” Chief Executive Officer of CureVac Dr. Franz-Werner Haas said.
As we reported, leaders of the major industrial nations have pledged more than two billion doses of coronavirus vaccines to poor countries as a "big step towards vaccinating the world”. It is noted that most of the doses will be supplied through the World Health Organization's Covax mechanism. The main funding will be provided by the leading Western industrial countries, in particular the European Union.